Immunic (IMUX) Earnings Date & Reports

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis... Show more

Industry: #Pharmaceuticals Major

Get AI intraday signals

A.I. Advisor

published Earnings

IMUX is expected to report earnings to rise 47.50% to -117 cents per share on November 05

Q3'26

Est.

$-1.18

Q2'26

Beat

by $0.43

Q1'26

Missed

by $1.00

Q4'25

Missed

by $0.53

Q3'25

Beat

by $0.02

The last earnings report on August 11 showed earnings per share of -80 cents, beating the estimate of -123 cents. With 83.65K shares outstanding, the current market capitalization sits at 226.23M.

View a ticker or compare two or three

IMUX

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days